PARP1 and hypopharynx cancer: We have been suggested that high expression of PARP1 enhances the radioresistance and Olaparib has a positive effect on the radiosensitization in hypopharyngeal cancer, providing an effective therapeutic strategy and improving their prognosis of hypopharyngeal cancer patients treated with radiation.